DB-3Q for Crohn's Disease

This trial explores a new treatment, DB-3Q, for individuals with Crohn's disease unresponsive to other medications. The goal is to determine if this approach, using a special product derived from bone marrow stem cells, is safe and effective. Participants will receive either the treatment or a placebo (a non-active substance) through an IV. This trial may suit those who have had Crohn's disease for at least six months and have not found relief from advanced immune therapies or can no longer use these treatments. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.

Yes, you may need to stop some medications before joining the trial. For example, monoclonal therapies must be stopped for at least 8 weeks, and certain other medications like cyclosporine and JAK inhibitors must be stopped for at least 4 weeks. Please check with the trial team for specific guidance on your medications.

Research shows that the safety of DB-3Q remains under investigation. This treatment uses tiny particles released by cells, derived from bone marrow stem cells. Although specific safety data for DB-3Q is not yet available, the current testing phase involves researchers closely monitoring participants' responses.

DB-3Q is unique because it offers a new intravenous approach to treating Crohn's disease, potentially providing a more direct and potent effect. Current treatments often involve oral medications like corticosteroids and immunosuppressants, which can take time to work and may have significant side effects. Researchers are excited about DB-3Q because it targets the condition through different doses (15 mL, 30 mL, 45 mL), which could allow for personalized treatment strategies. This could make DB-3Q more adaptable and effective, potentially offering faster relief for patients compared to traditional therapies.

Research has shown that DB-3Q, a treatment derived from special cells in bone marrow, may benefit people with Crohn's disease. One study found that more than half of the patients with Crohn's disease responded positively to DB-3Q. This trial will test different dosages of DB-3Q—15 mL, 30 mL, and 45 mL—to evaluate its effectiveness. The treatment might also aid those with complex anal fistulas caused by Crohn's disease. It uses tiny particles to facilitate cell communication, reducing swelling and supporting healing. Although further research is necessary, early results appear promising for individuals with Crohn's disease unresponsive to other treatments.¹²³⁶⁷